Welcome to our dedicated page for Atricure SEC filings (Ticker: ATRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AtriCure, Inc. filings document financial results, governance matters and capital arrangements for a Nasdaq-listed medical technology company focused on Afib, left atrial appendage management and post-operative pain management. Form 8-K reports furnish quarterly and annual results, amended financial guidance disclosures, product-revenue drivers and material definitive agreements, including an asset-based revolving credit facility involving AtriCure, LLC as a borrower.
Proxy filings cover board and shareholder voting matters, executive compensation, equity awards and related governance disclosures. The filings also identify AtriCure common stock as registered on the Nasdaq Global Market under the symbol ATRC.
AtriCure, Inc. CEO and President Michael H. Carrel, who also serves as a director, reported a charitable gift of 6,000 shares of AtriCure common stock on 11/13/2025, according to a Form 4 filing. The transaction used code “G,” indicating a gift, and was reported at a price of $0, with the filing noting that no consideration was received for this transfer.
After the reported transaction, Carrel beneficially owns 691,377 shares of AtriCure common stock directly. The filing also lists 9,310 shares held indirectly through his children and 2,250 shares held indirectly through his parents, with a statement that he disclaims beneficial ownership of these indirect holdings except to the extent of his pecuniary interest.
AtriCure (ATRC) reported solid third‑quarter growth and near break‑even results. Revenue rose to $134,269, up 15.8% year over year, with gross margin at 75.5% versus 74.9% a year ago. Operating income was $208, and net loss narrowed to $267, or $0.01 per share. For the first nine months, revenue reached $394,028, up 15.5%.
Growth was led by appendage management and pain management in the United States, while minimally invasive ablation declined as physicians shifted procedures. Cash and cash equivalents were $147,865 with long‑term debt of $61,865 and unused ABL borrowing availability of $61,885 as of September 30, 2025. The company completed enrollment of 6,500 patients in the LeAAPS trial and launched the cryoICE cryoXT probe for amputation pain therapy in the U.S. A sale‑and‑leaseback of a building resulted in a $6,250 financing obligation. Shares outstanding were 49,716,988 as of October 27, 2025.
AtriCure, Inc. (ATRC) filed an Amendment No. 1 to its Form 8-K to add the required signature of a duly authorized representative. The amendment makes no other changes to the original report filed on October 29, 2025.
The company also noted it issued a press release regarding financial results for the third quarter ended September 30, 2025, and scheduled a conference call on October 29, 2025 at 4:30 p.m. Eastern Time. The press release is furnished as Exhibit 99.1.
AtriCure (ATRC) furnished an 8-K announcing third-quarter results communications. The company issued a press release covering financial results for the quarter ended September 30, 2025 and scheduled a conference call on October 29, 2025 at 4:30 p.m. Eastern Time to discuss the results. The press release is provided as Exhibit 99.1 and is incorporated by reference as furnished information.
Insider sale by AtriCure officer: Justin J. Noznesky, Chief Marketing & Strategy Officer and director, sold 3,000 shares of AtriCure, Inc. (ATRC) common stock on 09/12/2025 at a weighted average price of $36.30 per share. After the transaction he beneficially owned 83,964 shares. The Form 4 discloses the sale price range ($36.28–$36.36) and states the reported price is a weighted average; the filer offers to provide detailed trade-by-trade information on request. The form is signed and dated 09/16/2025.
Sven Wehrwein, a director of AtriCure, Inc. (ATRC), executed matched transactions on 08/22/2025. He exercised 5,000 non-qualified stock options with an exercise price of $19.95, acquiring 5,000 shares. He simultaneously sold 5,000 common shares at $37.00. After these transactions he beneficially owned 34,374 shares and held options covering 35,000 shares exercisable through 11/11/2026. The options were originally granted on November 11, 2016, and vest per the schedule disclosed in the filing.
AtriCure, Inc. (ATRC) Form 144 discloses a proposed sale of 5,000 common shares through Morgan Stanley Smith Barney, with an aggregate market value listed at $185,000 and an approximate sale date of 08/22/2025. The filer states total shares outstanding of 49,701,415. The 5,000 shares were acquired on 08/22/2025 by stock option exercise from the issuer and paid in cash. The filing also lists a recent sale by the same person: on 08/19/2025 Sven Wehrwein sold 5,000 shares for $180,000. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Sven Wehrwein, a director of AtriCure, Inc. (ATRC), reported multiple transactions on 08/19/2025. He acquired 5,000 shares of common stock at $19.95 and sold 5,000 shares at $36, leaving him with 34,374 shares of common stock beneficially owned after the transactions. On the same date he was reported as acquiring a non-qualified stock option covering 5,000 shares with an exercise price of $19.95, reflecting a post-transaction total of 40,000 options. The filing notes these options were originally granted on November 11, 2016 and vest 25% after one year with the remainder vesting monthly over the following three years. The Form 4 is signed by Mr. Wehrwein on 08/21/2025.
A person affiliated with AtriCure, Inc. (ATRC) intends to sell 5,000 shares of the company's common stock through Morgan Stanley Smith Barney LLC on the NASDAQ. The notice lists an approximate sale date of 08/19/2025 and an aggregate market value of $180,000 based on that sale. The shares were acquired on 08/19/2025 through a stock option exercise from the issuer and payment was made in cash. The filer reports no securities sold in the past three months for the account covered by this notice and includes the standard representation that the seller does not possess undisclosed material information about the issuer.
This Schedule 13G reports that Macquarie entities beneficially own 2,503,205 common shares of AtriCure, representing 5.06% of the outstanding class (CUSIP 04963C209). The statement is jointly filed by Macquarie Group Limited, Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust. Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust each report sole voting and sole dispositive power over the 2,503,205 shares, while Macquarie Group Limited reports no sole voting or dispositive power. The filing includes a certification that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.